- 询价
- 钰博生物
- 进口/国产
- yb655254
- 2025年07月11日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-20℃
- 克隆性：
单克隆
- 抗体名：
Cyclin J-Like (CCNJL) (AA 125-153), (Center) 抗体
- 规格：
0.1ml/0.2ml
Cyclin J-Like (CCNJL)
别名 Gm877
抗原表位
其他选择 AA 125-153, Center
适用
其他选择 人
宿主
其他选择 兔
克隆类型 (克隆位点)
多克隆 (RB29134)
标记
其他选择 非结合性
应用范围
其他选择 Western Blotting (WB)
Pubmed 找到1个引用
规格 400 μL
发货至 中国 (更改)
发货时间 9至13个工作日
产品编号 yb655254
产品细节 Cyclin J-Like (CCNJL) (AA 125-153), (Center) 抗体
免疫原 This CCNJL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 125-153 AA from the Central region of human CCNJL.
克隆位点 RB29134
亚型 Ig
特异性 This CCNJL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 132-161 amino acids from the Central region of human CCNJL.
纯化方法 This antibody is purified through a protein A column, followed by peptide affinity purification.
目标详细情况 Cyclin J-Like (CCNJL) (AA 125-153), (Center) 抗体
别名 CCNJL
背景 Synonyms: CCNJL,Cyclin-J-like protein,
分子量 48406 DA
基因ID 79616
NCBI登录号 NP_078841
UniProt Q8IV13
研究领域 Cell Structure, Cell Cycle
使用细节 Cyclin J-Like (CCNJL) (AA 125-153), (Center) 抗体
应用备注 WB = 1:1000
限制 仅限研究用
贮存及处理 Cyclin J-Like (CCNJL) (AA 125-153), (Center) 抗体
状态 Liquid
浓度 0.25 mg/mL
缓冲液 PBS with 0.09 % (W/V) sodium azide
储存液 Sodium azide
注意事项 This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
储存条件 4 °C/-20 °C
储存方法 Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
有效期 6 months
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【转帖】[资源]液体芯片-飞行时间质谱技术在肿瘤早期诊断中的研究进展
first class hospitals and medical institutes, such as Women’s Hospital of Harvard University, Memorial Sloan-Kettering Cancer Center, General Hospital of Massachusetts, Baylor College of Medicine, where it was applied for the early diagnosis research of ovary
Interaction Trap/Two‐Hybrid System to Identify Interacting Proteins
Center, Boston, Mass. and M. Sainz and S. Nottwehr, U. Oregon (pNLexA); D.A. Shaywitz, MIT Center for Cancer Research, Cambridge, Mass. (pGilda); R. Buckholz, Glaxo, Research Triangle Park, N.C. (pEE202I, pJG4‐5I); J. Gyuris, Mitotix, Cambridge, Mass
University, Memorial Sloan-Kettering Cancer Center, General Hospital of Massachusetts, Baylor College of Medicine, where it was applied for the early diagnosis research of ovary cancer, prostate cancer, breast cancer, glioblastoma, head and neck squamous cell
技术资料暂无技术资料 索取技术资料
